钇-90肝动脉放射栓塞治疗晚期化疗难治性转移性结直肠癌:基于原发肿瘤左/右半位置的生存结局
该单中心回顾性研究纳入99例化疗难治性转移性结直肠癌肝转移患者,均接受钇-90树脂微球放射栓塞。右半原发肿瘤患者放射栓塞后中位总生存期低于左半患者(5.4 vs 6.2个月,p=.03),但RECIST肿瘤反应、肝内无进展生存期及肝外进展无显著差异。
要点
- 右半原发肿瘤与钇-90放射栓塞后生存期降低独立相关,中位生存5.4 vs 6.2个月(p=.03)。
- 首次影像随访RECIST进展者生存期短于疾病控制者(4.0 vs 10.5个月,p<.001)。
- 左半肿瘤组中RECIST进展者生存期显著更短(4.2 vs 13.9个月,p<.001),右半组未达统计学显著(3.3 vs 7.2个月,p=.05)。
临床应用与阅片要点
- 原文结论指出原发结肠癌位置影响挽救性钇-90放射栓塞后的结局,可能有助于指导患者选择。
- 首次影像随访按RECIST评估为进展者,其放射栓塞后中位总生存期短于疾病控制者(4.0 vs 10.5个月,p<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND. Primary colon cancer location affects survival of patients with metastatic colorectal cancer (mCRC). Outcomes based on primary tumor location after salvage hepatic radioembolization with 90Y resin microspheres are not well studied. OBJECTIVE. The objectives of this study are to assess the survival outcomes of patients with advanced chemorefractory mCRC treated with 90Y radioembolization, as stratified by primary tumor location, and to explore potential factors that are predictive of survival. METHODS. A total of 99 patients who had progressive mCRC liver metastases while receiving systemic therapy and who were treated with 90Y radioembolization at a single center were retrospectively analyzed. For 89 patients, tumor response on the first imaging follow-up examination (CT or MRI performed at a mean [± SD] of 1.9 ± 0.9 months after 90Y radioembolization) was evaluated using RECIST. Overall survival (OS), OS after 90Y radioembolization, and hepatic progression-free survival (PFS) were calculated using the Kaplan-Meier method. Outcomes and associations of outcomes with tumor response were compared between patients with left- and right-sided tumors. RESULTS. A total of 74 patients had left-sided colon cancer, and 25 patients had right-sided colon cancer. Median OS from the time of mCRC diagnosis was 37.2 months, median OS after 90Y radioembolization was 5.8 months, and median hepatic PFS was 3.3 months. Based on RECIST, progressive disease on first imaging follow-up was observed in 38 patients (43%) after 90Y radioembolization and was associated with shorter OS after 90Y radioembolization compared with observation of disease control on first imaging follow-up (4.0 vs 10.5 months; p < .001). Patients with right-sided primary tumors showed decreased median OS after 90Y radioembolization compared with patients with left-sided primary tumors (5.4 vs 6.2 months; p = .03). Right- and left-sided primary tumors showed no significant difference in RECIST tumor response, hepatic PFS, or extrahepatic disease progression (p > .05). Median survival after 90Y radioembolization was significantly lower among patients with progressive disease than among those with disease control in the group with left-sided primary tumors (4.2 vs 13.9 months; p < .001); however, this finding was not observed in the group with right-sided primary tumors (3.3 vs 7.2 months; p = .05). CONCLUSION. Right-sided primary tumors were independently associated with decreased survival among patients with chemorefractory mCRC after 90Y radioembolization, despite these patients having a similar RECIST tumor response, hepatic PFS, and extrahepatic disease progression compared with patients with left-sided primary tumors. CLINICAL IMPACT. Primary colon cancer location impacts outcomes after salvage 90Y radioembolization and may help guide patient selection.
引用
- Wu V, Li MD, Goodwin JS, et al. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location. AJR Am J Roentgenol. 2021. PMID: 33594907. doi:10.2214/AJR.20.25315
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。